Race Oncology Limited

Race Oncology Limited

RAONF
Race Oncology LimitedUS flagOther OTC
2.60
USD
+1.38
- -
451.73MMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
-0.08
-0.09
-0.05
-0.04
-0.05
-0.07
-0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
0.07
0.05
0.02
0.04
0.07
0.18
0.11
- -
Tangible Book Value per Share
- -
- -
0.03
0.05
0.01
0.02
0.08
0.21
0.14
- -
Basic Weighted Avg Shares
- -
11
53
67
80
107
131
153
161
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-4
-6
-4
-4
-6
-11
-10
-14
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
3
- -
1
3
1
2
10
33
22
16
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
7
- -
6
8
5
6
14
36
25
18
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-223.3
-170.85
-129.75
-130.72
-98.16
-59.95
-42.73
-99.99

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
51.88%
-28.15%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
34.9%
39.26%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.07
2023
- -
- -
- -
- -
-0.06
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Daniel Tillett
Sector
Healthcare
Industry
Biotechnology
Address
Gateway, 1 Macquarie Place Sydney NSW Australia 2000
IPO Date
Mar 9, 2021
Business
Race Oncology Limited (ASX:RAC; OTC:RAONF) is an Australia-based clinical-stage biopharmaceutical company focused on developing novel oncology treatments that address unmet needs in cancer care by enhancing anticancer efficacy and reducing cardiotoxicity. Founded in 2011 and headquartered at Level 36, 1 Macquarie Place, Sydney, New South Wales, the company develops RC220, a proprietary reformulated version of bisantrene, a small-molecule chemotherapeutic originally evaluated in over 50 clinical trials involving more than 1,500 patients; RC220 targets G4-DNA and RNA binding to inhibit the MYC cancer growth regulator, demonstrates lower cardiotoxicity than anthracyclines like doxorubicin, and shows potential cardioprotection when combined with anthracyclines in solid tumors including breast cancer and non-small cell lung cancer, as well as acute myeloid leukemia (AML). Its pipeline emphasizes anthracycline combination therapies for advanced solid tumors, m6A RNA pathway modulation via FTO inhibition, and next-generation FTO inhibitor candidates discovered through fragment-based screening at Monash University. The company conducts Phase 1 clinical trials, such as RAC-010 evaluating RC220 plus doxorubicin safety, tolerability, and pharmacokinetics in advanced solid tumor patients at sites including Southside Cancer Care Centre in New South Wales, with expansion into Asia featuring open sites in Hong Kong and forthcoming recruitment in South Korea; it plans Phase 2b CPACS-2, Phase 3 AML efficacy expansion, and HARNESS-1 lung cancer trials starting in Q1 2026. Race Oncology collaborates with global institutions including Astex, City of Hope, MD Anderson Cancer Center, Sheba Medical Center, UNC School of Medicine, University of Wollongong, and University of Newcastle, while actively pursuing additional partnerships, license agreements, or mergers to accelerate RC220 commercialization worldwide. Recent developments include execution of a contract in March 2025 with Emerald Clinical Trials (formerly George Clinical) for clinical operations support; appointments to strengthen leadership such as Professor Daniel Von Hoff to the Clinical Advisory Board and Dr. Jose Iglesias and Dr. Simon Fisher to medical roles, alongside Dr. Megan Baldwin as Independent Non-Executive Director effective January 2025 and board changes with Dr. Pete Smith as Chairman in August 2024; adoption of a new constitution at the 2025 AGM to enhance governance; receipt of $2.8 million R&D tax refund in November 2025 for FY2025 with further expected; breakthrough composition-of-matter IP discovery in September 2025; and financial positioning to fund ongoing trials through end-2027 while evaluating capital raises including option conversions. Operations remain centered in Australia with global clinical and research reach, targeting adult and pediatric cancer patients across multiple indications.

Company News

APIChat